Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John McCullough

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Science (New York, N.Y.)|July 10, 2025
Tissue-integrated bionic knee restores versatile legged movement after amputationTony Shu, Daniel Levine, Seong Ho Yeon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2023
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and AdultsAndrew W Lee, Ken Liu, Edouard Lhomme, et al.
The New England Journal of Medicine|November 5, 2025
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine CandidateElissa Malkin, Marija Zaric, Mark Kieh, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Science (New York, N.Y.)|July 10, 2025
Tissue-integrated bionic knee restores versatile legged movement after amputationTony Shu, Daniel Levine, Seong Ho Yeon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2023
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and AdultsAndrew W Lee, Ken Liu, Edouard Lhomme, et al.
The New England Journal of Medicine|November 5, 2025
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine CandidateElissa Malkin, Marija Zaric, Mark Kieh, et al.
Pageof 4